AcelRx Pharmaceuticals (NASDAQ:ACRX) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.53) by 24.53 percent. This is a 66.67 percent increase over losses of $(1.20) per share from the same period last year. The company reported quarterly sales of $253.00 thousand which beat the analyst consensus estimate of $70.00 thousand by 261.43 percent. This is a 55.61 percent decrease over sales of $570.00 thousand the same period last year.